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Abstract
The Shannon Human Splicing Pipeline software has been developed to analyze variants on a
genome-scale. Evidence is provided that this software predicts variants affecting mRNA
splicing. Variants are examined through information-based analysis and the context of novel
mutations as well as common and rare SNPs with splicing effects are displayed. Potential
natural and cryptic mRNA splicing variants are identified, and inactivating mutations are
distinguished from leaky mutations. Mutations and rare SNPs were predicted in genomes of
three cancer cell lines (U2OS, U251 and A431), supported by expression analyses. After
filtering, tractable numbers of potentially deleterious variants are predicted by the software,
suitable for further laboratory investigation. In these cell lines, novel functional variants
comprised 6–17 inactivating mutations, 1–5 leaky mutations and 6–13 cryptic splicing
mutations. Predicted effects were validated by RNA-seq data of the three cell lines, and
expression microarray analysis of SNPs in HapMap cell lines.

Keywords
Mutation, mRNA splicing, information theory, next-generation sequencing, genome
interpretation, bioinformatics, biological pathway analysis, cancer.
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A431 - epidermoid squamous carcinoma-derived cell line.
API – A library of functions, data structures, classes, etc. which can be exploited by a
programmer.
ASSA - Automated splice site analysis server. A tool to predict the effects of sequence
changes that alter mRNA splicing in human diseases.
dbSNP – Single Nucleotide Polymorphism database. A public-domain archive of single
nucleotide polymorphisms.
GCC – GNU Compiler Collection. The standard compiler for most Unix-line operating
systems.
FASTA format – A text-based file containing nucleotide sequences (can also contain
peptide sequences) for one or more region in a genome.
hg18 – Also called NCBI36. The March 2006 human reference sequence.
hg19 – Also called GRCh37. The February 2009 human reference sequence. The most
recent patch is GRCh37.p11. Patch data generally contains alternate haplotype regions.
HGNC – HUGO Gene Nomenclature Committee. HUGO- or HGNC-approved.
HUGO – Human Genome Organisation.
Indel - A genomic insertion or deletion. Indels range in size from a single nucleotide to
multiple kilobases.
Java Swing – The primary Java GUI toolkit. It is an API which provides graphical user
interface design functionality.
NGS – Next generation sequencing.
NMD – Nonsense-mediated mRNA decay. A surveillance pathway which reduces errors
in gene expression by eliminating mRNA transcripts that contain a premature stop codon.
PCR - Polymerase chain reaction. Used to amplify a small number of (or one) DNA
segments, resulting in many copies of the sequence.
qPCR – Quantitative real-time polymerase chain reaction. For one or more specific
sequences in a sample, sequences can be detected and quantified.
Ri - Information content in bits.
RNA-seq – Uses high throughput sequencing to sequence cDNA in order to measure the
levels of RNA transcripts and their isoforms in a sample.
SNP – Single nucleotide polymorphism. A single-nucleotide substitution in the genome.
A SNV that has been characterized.
SNV – Single nucleotide variant. A single-nucleotide substitution in the genome.
U251 - glioblastoma-derived cell line
U2OS - osteosarcoma-derived cell line
VUS- Variant of Unknown Significance. A variant which has been documented but has
no known pathogenic significance.
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1

Introduction

The volume of human next-generation sequencing (NGS) data requiring bioinformatic
analysis has necessitated development of high-performance software for genome scale
assembly and analysis 1. Genomic variations found in these analyses, particularly single
nucleotide polymorphisms (SNPs), have traditionally been interpreted in terms of amino
acid modifications in coding regions. Clinically-significant non-coding variants are a
relatively unexplored source of pathogenic mutations and lack a general, high-throughput
method to interpret their effects. In this thesis I present genome-scale software which I
adapted and further developed to quantify the effect of mutations in the common classes
of splice donor (U1) or acceptor (U2)-type sites in a high-throughput manner. Mutations
predicted with this method will be useful for pinpointing potentially deleterious variants
suitable for further laboratory investigation.
Clinical studies have deemed the vast majority of known variants in patients with
Mendelian (single-gene) disorders to be of uncertain pathogenic significance (VUS)

2,3

.

Cis mutations can affect protein translation, mRNA processing and initiation of
transcription. In silico methods have been developed for the first two of these cases (e.g.,
4,5

), but have only been routinely applied for protein coding changes in genome-scale

applications (e.g., 6). Many NGS studies classify splicing mutations only as those located
within the highly conserved dinucleotides within each splice junction (e.g.,7). Although
more sensitive methods have been developed which assess other conserved sequence
elements 8-12, none have been scaled for the large numbers of variants generated by NGS
and nor have they been validated for this data. Exonic variants in close proximity to
splice junctions but outside of this window may be classified as synonymous, missense or
nonsense substitutions, yet still have profound effects on splicing, which may be the
predominant contributor to the phenotype. Unless multiple affected patients are reported
with the same mutation, the mutations are transmitted through pedigrees, and functional
assays verify their effects, these variants in patients are generally classified as VUS.
mRNA splicing mutations are common in Mendelian diseases

13,14

, and it is likely that

they contribute to many complex disorders. Clearly, genome-scale predictive methods

2

that filter out benign or small changes in mRNA splicing due to sequence variation will
be essential for mutation discovery in exomes, complete genomes and high-density
targeted deep sequencing projects. Examination of individual variants in the laboratory
with functional assays is both expensive and inefficient as many variants are not likely to
be deleterious, or differ significantly in their pathogenicity.
The Automated Splice Site Analysis (ASSA)

5

server evaluates single mutations that

change splice site strength with information-based models

15

. The average information,

Rsequence, of a set of binding sites recognized by the same protein (such as U1 or U2)
describes the conservation of these sequences. Sequences are ranked according to their
individual information content (Ri in bits)

15-17

. Individual information content is a

portable, universal measure which allows direct comparison of binding sites across the
genome or transcriptome, regardless of the sequence or protein recognizer. Functional
binding sites have Ri > 0, corresponding to ∆G < 0 kcal/mol 18. Strong binding sites have
Ri >> Rsequence, while weak sites have Ri << Rsequence. Any sequence variation may change
its protein binding affinity, which is reflected by a change in the computed Ri of that
binding site. A 1-bit change in information content (∆Ri) corresponds to a ≥ 2 fold change
in binding affinity (100/2∆Ri). The ASSA server has been widely used and its sensitivity
and specificity has previously been extensively validated in hundreds of studies of
individual mutations (http://tinyurl.com/splice-server-citations). However, it requires
approximately 30 seconds to examine a single variant and is therefore not suitable for
comprehensive analysis of whole-genome sequencing data. The Shannon pipeline was
implemented using the same mathematical approach and information weight matrices as
ASSA to carry out batch information-based analysis of thousands of mutations from the
BRCA1 and BRCA2 genes in the Breast Cancer Information Core Database

19

. In the

present study, the software has been adapted to perform a single matrix algebraic
calculation across a genome with an efficient state machine that significantly increases
computational speed over ASSA.
During the tenure of my M.Sc. I was involved in the release of three papers
thesis, I will present work described in 20. My contribution in

21

20-22

. In this

was the implementation

an algorithm which determines single-copy regions (regions not repeated elsewhere in the

3

genome) without the use of a catalogue of repetitive sequences. This work allowed me to
appreciate the scope and sheer size of genome-scale programming projects. In particular,
although my program was executed on the Shared Hierarchical Academic Research
Computing Network (SHARCNET) using 128 cores, the full execution time of the
software was ~3 months. This inspired me to become involved with a software project
operating on a genome-scale, which executed in a far shorter time. Additionally, my role
in

22

was to assist in modifications to ASSA (and the newer ASSEDA). Implementing

these modifications improved my understanding of molecular information theory and its
applications related to splicing prediction.
Several years ago, C libraries were developed by Tyson Whitehead which calculate the
information content of a genomic region based on information weight matrices

19,20

.

These libraries were designed to execute very quickly while not sacrificing specificity.
Chromosomes are stored in memory one at a time and each base is stored using 17 bytes.
The longest human chromosomes can therefore be represented using a few gigabytes of
memory. Reference sequences for each chromosome are read from FASTA files and
parsed at disk speed (parsed as fast as the disk can read the file). As a consequence, the
libraries require only several seconds to parse each chromosome. Sequence blocks, four
kilobytes in size, are extracted from the appropriate region of a parsed FASTA file and
information analysis is performed. As the appropriate regions of the genome are extracted
from memory on demand there is no need for indexing, thus execution speed is highly
optimized.
In this thesis I describe the development of software which extends these C libraries.
Variants are annotated, stratified, ordered in terms of relevance, presented in a userfriendly manner, and the code is integrated with the CLC-Bio Workbench. Predicted
deleterious mutations are compared with RNA-seq data from genomes of three cancer
cell lines to assess their validity.

4

2

Literature Review

2.1 Overview of splicing mechanisms
The human genome contains approximately 3,000,000,000 nucleotides 23. It is comprised
of DNA which is made up of four nucleotides - adenine, thymine, cytosine, and guanine denoted A, T, C, or G joined by phosphodiester bonds. These nucleotides form a code
which eventually translates into proteins necessary for survival. Nucleotides (bases) can
form base pairs with other nucleotides. For each base, there is another nucleotide which
binds to it called its complementary base. The base A binds readily to the base T, and G
binds with C. Base pairs are formed by hydrogen bonds (AT and GC base pairs
experience 2 or 3 hydrogen bonds respectively). In the genome, DNA forms its double
helix structure by pairing a strand to another complementary strand. Only ~1.1% of DNA
directly codes for proteins and these regions are referred to as exons. Collections of exons
and non-coding regions called introns between them (along with other regulatory
elements such as promoters, enhancers, etc.) form genes. To ensure proper gene function,
introns must be precisely removed to result in an mRNA suitable for translation to protein
24

.

2.1.1 The spliceosome and the splicing process
Introns are bound by conserved sequences that define their 5′ and 3′ ends. The
spliceosome is comprised of small nuclear RNA (snRNA) and protein and is a
macromolecule which excises introns during splicing. During transcription to RNA, the
spliceosome acts in two major steps. First, the 5′ splice site base pairs with the U1
snRNA which is part of the spliceosome and splicing factor 1 (SF1) binds to the branch
point, located upstream of the 3′ splice site

25

. The 5′ splice site and branch point are

drawn together, and the 5′ splice site undergoes a nucleophilic attack which breaks the
phosphodiester bond at the splice junction and simultaneously forms a linkage between
the branch point and the 5′ end of the intron. This results in an intron conformation
structure similar to a lariat. In the second step, the newly released 3′ hydroxyl of the 5′
exon attacks the 3′ splice site. Again, the phosphodiester bond at the splice junction is
broken, and in its place a bond is formed between the two exons 24.

5

2.1.2 Donor and acceptor splice sites
Located at each end of an intron is a splice site denoted as a donor site at the 5′ end of the
intron or acceptor site at the 3′ end. Both of these sites are referred to as natural sites (the
splice site used in the absence of mutation). The efficiency of splicing is partially
determined by the highly conserved GT and AG dinucleotides present at the donor and
acceptor sites, respectively. These dinucleotides are certainly not the sole determinants of
normal splicing however. The length of donor and acceptor sites have been defined as
10bp (-3, +6) and 28bp (-25, +2) respectively where 0 refers to the first nucleotide of the
splice junction

26

. In 1986, a study examined approximately 400 vertebrate genes and

derived consensus sequences for both donor and acceptor sites

27

. The strong

conservation of these regions was evident – even across species barriers – which implied
an important role in splicing.
Point mutations within splice sites affecting pre-mRNA splicing account for
approximately 15% of human genetic disease

28

. Mutation within any region of a donor

or acceptor site can contribute to a reduction (or in rare cases, a strengthening) of the
site’s binding affinity to the spliceosome. Weakened natural sites may cause aberrant
splicing.

2.1.3 Splice site recognition and variation
Proper definition of donor and acceptor sites is central to proper RNA and protein
formation. Splicing machinery is tasked with locating exons (137 nucleotides long on
average) separated by much longer intronic regions

29

. This task is made more difficult

through the existence of “decoy” sites (cryptic splice sites). These sites contain similar
sequences to splice sites and must be accounted for. If splicing machinery relied only on
nucleotide sequence, cryptic sites would be frequently used in place of natural sites (sites
which are generally used barring genetic variation). In 1994, a study catalogued instances
mammalian splice site mutation

30

. In this study, four phenotypes were observed as a

result of splice site mutation. Exon skipping, cryptic site use, creation of a pseudo-exon
entirely within an intron, and intron retention were observed. In particular, 55% of
observed phenotypes demonstrated exon skipping. The prevalence of exon skipping

6

(when only one splice site of an intron is affected) implied that splice sites are recognized
as pairs 29. In addition, the size of exons is also a factor. Only 3.5% of exons are of length
>300 nucleotides and less than 1% >400. This again implies that the sequence of splice
sites is not the only determining factor in splice site recognition.
Up to ~50% of deleterious alterations in genes may be caused by splicing mutations

31

.

Although mutations located anywhere in a gene can impair the splicing process, most
deleterious variants have been found in the GT/AG dinucleotides located at splice
junctions

31

. The GT/AG nucleotides are highly conservered. However, any nucleotide

substitutions within splice sites may alter splicing outcome. There are three main
potentially deleterious outcomes which can occur as a result of variation within splice
sites (Figure 1). A mutation may weaken a splice site to such a degree that it no longer
functions effectively. This may cause the affected exon to be missing from the resulting
mRNA (exon skipping) or the exon to extend past the natural site into the intron (intron
inclusion). Other mutations may weaken a splice site to a degree insufficient to cause
exon skipping. Mutations of this type may result in a lesser expression of a normal splice
isoform (leaky). Finally, mutations that strengthen nearby cryptic sites or weaken a
natural site with a cryptic site nearby may lead to cryptic site binding. Cryptic site
binding may shorten or extend an exon. Multiple mRNA splice isoforms can be
produced. Variation in the nucleotide sequence of donor or acceptor sites can increase or
decrease the abundance of a specific isoform in the population of mRNA.

2.2 Molecular information theory
Information theory was first devised by Claude E. Shannon and published in his article
“A Mathematical Theory of Communication, Part I.” in 1948. It is a branch of
mathematics used to quantify information and determine the information content in a
system. Two main aspects of communication are addressed; 1) methods to measure
information, and 2) determination of the maximum information which can be sent and
received through a communications system.

7

Figure 1. Types of splicing mutations that affect structure and/or abundance of
resulting transcripts
The diagram illustrates potential outcomes of mRNA splicing mutations predicted by the
Shannon pipeline. Intervening sequences (IVS) contain an intron and other nucleotides
not present in the resulting mRNA. Variation within splice donor and/or acceptor sites
may lead to altered splicing events such as exon skipping (◊), exonic (□) or intronic (△)
cryptic site use, and/or reduction in the abundance of normally spliced mRNA forms,
termed leaky mutations (○).

8

2.2.1 Basics of molecular information theory
Molecular information theory describes biological interactions by exploiting the
mathematics of information theory 32 and applying it to biological systems. In particular,
information-based methods can be used to calculate the information content of binding
sites recognized by one kind of macromolecule (e.g., the spliceosome). Known binding
sites must be aligned and examined, however the contributions of individual positions are
not ignored as they are in consensus sequences. A consensus sequence aligns sequences
and reports the most prevalent base at each position. The information content of sites
recognized by a single macromolecule is denoted Rsequence. Two sources of information
are needed to compute Rsequence: 1) The nucleotide sequences where a macromolecule has
demonstrated the ability to bind. 2) The sequences must be viewed in the context of an
entire communication system. Thus, the nucleotide composition of the genome in which
the macromolecule functions must be determined 33.
Sequences recognized by a single macromolecule within a genome known to experience
macromolecule binding are aligned in a manner to allow the greatest homology between
bases. The Rsequence of the site can then be calculated. The general formula for uncertainty
can be modified as follows to represent nucleotide sequences
(2.1)

where B = {A,C,G,T}, and f (B,L) is the frequency of base B in position L is found in the
sequence. This equation can be applied to a full genome by exploiting existing data on
the nucleotide content of the human genome. If a set of random nucleotides sequences
were extracted from the human genome and aligned, all four bases would be observed,
with probabilities P(B). Thus, the equation can be modified as follows
(2.2)

9

When this formula is applied genome-wide, the resulting uncertainty is higher than when
applied to only known binding sites. This implies there is a pattern in the nucleotide
sequences located at splice sites. This was certainly an expected result, as splice site
sequences were known to be conserved. For each position L, that decrease in uncertainty
can be demonstrated by
(2.3)

Rsequence(L) is therefore a measure of the information gained (uncertainty lost) by aligning
the binding sites. Information is additive

16

, thus the total information gained is equal to

the decrease in uncertainty across all sites
(2.4)

where Hnb is the probability of obtaining a particular combination of n bases. Although
information itself is additive, this equation has been simplified by assuming that the
frequencies of bases observed at one position are statistically independent of any other.

2.2.2 Information weight matrices
Information content can be defined as the number of choices needed to describe a
sequence pattern, using a logarithmic scale in bits

33

. These data can be represented as a

weight matrix calculated by
(2.5)
Riw(b,l) (also referred to as RIBL) is a two dimensional array containing b rows and l
columns where b = {A,T,C,G}, l is the position in the splice site, and e(n(l))) is a sample
size correction factor for the n sequences at position l used to create f(b,l). The 2
represents the bits of uncertainty a recognizer has before binding to a site containing 4
possible bases (log2(4)). As a whole, this matrix represents the sequence conservation of
each nucleotide, measured in bits and can be exploited to compare sites to one another,
search for new sites, to compare sites to other quantitative data such as DNA-protein

10

binding strength, and other applications 34. The most frequent base at each position of the
weight matrix is assigned the largest individual information (Ri in bits) value. Therefore,
a consensus sequence can be generated by selecting the highest Ri value at each position.
The individual information of a sequence can be compared to an information weight
matrix in the following way
(2.6)

where j is an individual sequence and s(b,l,j) is a simple two dimensional array which
represents the jth sequence. As j is a single sequence, frequencies are not involved in this
matrix as such. Instead, elements in s(b,l,j) contain the value 0 at every position with the
exception of base b at position l which contains 1.

2.2.3 Information theory and human splicing site mutations
The human genome can be viewed as a system which contains information. As is widely
known, DNA triplets code for the synthesis of specific amino acids. However, this is not
the only kind of information stored within the genome. As discussed in chapter 2.1, splice
sites are comprised of similar, conserved DNA sequences. Information can be described
as a decrease in uncertainty, therefore the similarity of splice sites implies that they
contain information.
The effects of genetic variation (base substitutions) within a sequence can be calculated
by examining the Ri or the common and variant alleles. The difference between their
respective information contents is denoted as ΔRi. As Ri is on a logarithmic scale, the
minimum change in binding affinity of two sites is 2ΔRi
computed for 56,985 acceptor and 56,286 donor sites

35

15

. Riw(b,l) matrices have been

. Matrices used by the Shannon

pipeline are based on these models and were obtained using the same method, but are
based on sites on both strands. Models in 35 were based on only on the positive (+) strand.
Matrices used by the pipeline are based on 108,079 acceptor sites and 111,772 donor
sites. The mean distribution of Ri values across these sites is denoted Rsequence where the
Rsequence of donor and acceptor sites are computed separately. Therefore, Rsequence

11

represents the average information required for splicing to occur at a splice site. It also
reflects the strength of the splice site. Those splice sites which have Ri values << Rsequence
are weak sites, while those with Ri >> Rsequence are strong sites. Non functional sites have
Ri values less than ~1.6 bits.

12

3

Shannon pipeline - Methods

3.1 Shannon pipeline software architecture
I have implemented the Shannon pipeline plugin using the CLC-Bio genomics developer
toolkit to simplify access to this technology and interpretation by novice users. The same
plugin can be executed on a single client computer, a remote server or a grid system, and
benefits from automated software updates. The server version uses an architecture in
which a Workbench client transmits variant data to the server, which performs the
computations, and returns results that can be filtered and formatted on the client. A
standalone version of the fully functional Genome Workbench plugin is also available.
By contrast, the splicing mutation feature that is native in CLC-Bio Genomics’ products
is limited to detecting changes in dinucleotides at the exon boundaries, which represent
fewer than 5% of all splicing mutations detected by the Shannon pipeline.
The Shannon pipeline uses an efficient algorithm coded in C to quickly analyze genomescale data sources for information changes (Figure 2). Methods for computing Ri and Ri
values determine the dot product of an information weight matrix and the unitary
sequence vector for each genomic window and comparing the resultant scalar values of
the reference and variant sequences 36. C libraries determine the information content of a
position in the reference genome and after a variant is introduced. This method uses
convolution-style sliding-window computation of all sequence changes for each complete
chromosome sequence resident in RAM. To expedite processing, the software currently
only handles single nucleotide variants (SNV) – which are the most prevalent type of
variation. Changes in Ri introduced by genomic variation are computed by subtracting the
initial Ri value of a position by the sum over a surrounding window, then adding the new
value for each position (∆Ri). Perl scripts wrap these C libraries and annotate output.
Integration with the CLC-Bio Workbench environment was achieved through code
written in Java utilizing the CLC-Bio developer API. This software is assembled as a
client plugin requiring a connection to the server to execute, a server plugin and a
standalone client plugin. Two additional dependency plugins contain a modified
dbSNP135 (containing only variant, rsID and overall frequency), Ensembl Exon Data

13

(Build 66) and GRCh37 (hg19)/NCBI36 (hg18), respectively, allowing the software to
execute with no active internet connection and incorporates all necessary annotations
required to contextualize a potential mutation.
Input flat files containing sequence variants that differ from the reference genome are
imported into the CLC-Bio Java environment. The file must be either Variant Call
Format (VCF)

37

or a tab-delimited format with the following fields: [chromosome #]

[unique identifier] [coordinate] [reference/variant]. Coordinates can be hg18 or hg19. All
variants appearing in this study are hg19. Genomic insertions and deletions (indels)
present in input files are not considered for analysis.

3.2 Perl scripts and modules
Two Perl scripts were previously written to perform variant annotation. I significantly
modified these scripts by increasing memory/time efficiency and modularizing the code
to simplify testing. To this end, I divided the two preexisting scripts into 5 Perl modules.
I wrote an additional two Perl scripts and several modules to automate plugin installation
and filtering of variants. I will briefly describe the functionality of the scripts and
modules here. A straightforward Perl script that splits variants on each chromosome into
separate files will not be described.

3.2.1.1

MainControl.pl

This script is executed from within Java code and serves as part of the connection
between command-line code and the CLC-Bio Workbench. More details related to this
interconnectivity can be found in section 3.3.1.6. Standard output and standard error are
redirected stdout.log and stderr.log respectively. This was done to allow detailed error
messages to be effectively communicated to the CLC-Bio Workbench. The main purpose
of the script is to call a series of Perl modules which each append some annotation to an
array of data. The array is passed by reference from each module back to MainControl.pl
and passed to the next module. The script also updates a variable containing a
rudimentary progress percentage which is sent to the Workbench every 5 seconds. It is
used to update a progress bar displayed to the user. Between the execution of each
module the progress percentage is updated to an increased value.

14

Figure 2. Flow chart of the Shannon Human Splicing Pipeline.
Client and server tasks are depicted separately. Interactions between them are denoted by
arrows crossing the client/server barrier. The pipeline can also be executed on the client
in a standalone manner. In that case, all server actions are performed on the client
machine.

15

3.2.1.2

InstallShannonPipeline.pm

C libraries must be compiled before they can be executed. The C libraries are installed as
Perl modules through the use of preexisting Perl wrappers. This Perl module
automatically compiles the libraries if necessary. To check if the libraries are already
installed I use “eval ‘require Rogan::FASTA” (Rogan::FASTA is the name of one of the
modules). If the module is already installed, installation will not take place. Otherwise, a
series of commands will be run, some of which are used for potential error reporting. The
current directory is changed to the location where the libraries will be installed and the
date and current directory are sent to stdout.log. All external commands are run by calling
Perl’s system function using an array constructed specifically for each command. The
commands are:
1) my $makeClean = qq(make clean 2>> ./stderr.log 1>> ./stdout.log);
2) my $createMakefile = qq(perl Makefile.PL LIB="./installeddir/" PREFIX="./extras/"
2>> ./stderr.log 1>> ./stdout.log);
3) my $makeCommand = qq(make 2>> ./stderr.log 1>> ./stdout.log);
4) my $makeInstall = qq(make install 2>> ./stderr.log 1>> ./stdout.log);
Command number 2 specifies LIB and PREFIX options to allow local installation
without the need for root access. Each command is executed using system. System error
codes are trapped and examined. If an error occurs in any of these steps, execution stops
and error code 100 is sent to the Workbench, indicating a problem with installation.

3.2.1.3

Pipeline-Initial-Scan.pl

A parameters file created by Java code is examined to determine the location of
appropriate FASTA files containing the reference genome, as well as the location of
donor and acceptor information weight matrices. Chromosomes are examined one at a
time. Before variants on a chromosome can be examined, the appropriate FASTA file is
parsed into an efficient state machine using a C library. Donor and acceptor information
weight matrices are also parsed. Each variant is examined using C libraries to determine
its Ri before and after the contribution of a specific variant. The following information is
written to a file for each variant: 1) chromosome, 2) variant unique ID, 3) splice site
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coordinate, 4) Ri before variant contribution, 5) Ri after variant contribution, 6) donor or
acceptor site, 7) strand, 8) variant coordinate, 9) variant (e.g., G/T). The process is
repeated for all chromosomes.

3.2.1.4

WriteTracksAndFindIfWithinGene.pm

In addition to plot and tabular output, BED tracks are also generated by the pipeline. The
tracks contain ΔRi for each variant and can be viewed in a genome browser. The module
reads the file generated by Pipeline-Initial-Scan.pl line by line. Hash tables are created
which allow constant time searches named donorpos (positive strand, donor), donorneg,
accpos, and accneg. Each variant is sent to a generalized function which accepts the
appropriate hash, file handle to write to (appropriate track), chromosome number, and
variant ΔRi. This function simultaneously appends to the appropriate track file as well as
adding each variant to the appropriate hash.
Ensembl Gene 66 is examined along with the list of variants. If a variant is found within
transcript start and end coordinates, then it is within a gene. Variants meeting that
requirement are added to an array which is returned by reference to MainControl.pl.
Variants not found to be within an exon are not annotated further.

3.2.1.5

AnnotateNaturalSites.pm

This module determines if there is a nearby natural site close to the variant. The array of
variants found to be within an exon by WriteTracksAndFindIfWithinGene.pm are
examined along with natural site coordinates found in Ensembl Gene 66. Hash tables are
built containing the locations of donor and acceptor natural sites on both strands. If a
variant is found to affect a known natural site the variant is annotated as a natural site.
Otherwise it is annotated as a cryptic site. The array is returned to the main Perl script for
further annotation.

3.2.1.6

AnnotateExons.pm

Each variant within a cryptic site is examined to determine if there is a natural site
nearby. The presence of a natural site allows the cryptic and natural site to be directly
compared to one another. It can be determined if the cryptic site flanks the 3′ or 5′ end of
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the exon and Ri values of the cryptic and natural site can be compared after the
contribution of the cryptic variant is observed. The range to check for a nearby natural
site is determined by a field in the parameters file created using Java code. Currently, this
value is 300. Thus, a range of up to 300 bp around the cryptic site is examined and
compared with natural sites from Ensembl Gene 66. Variants near a natural site are
annotated 3′ or 5′ flanking and returned.

3.2.1.7

GetStrengthsOfNearestNaturalSites.pm

Nearby natural sites potentially found in AnnotateExons.pm are compared with the
appropriate variant cryptic site to determine which site has the higher Ri value. If the
nearby natural site has the higher Ri, the variant is annotated as greater. Otherwise the
variant is annotated as less. If a variant does not have a nearby natural site within 300bp,
a ‘-‘ is annotated to the variant as a placeholder. The resulting variants are returned for
further annotation.

3.2.1.8

AnnotateKnownVariants.pm

It must be determined if a variant has been previously documented in dbSNP or if it is a
novel variant. The array returned from the previous module is used to generate a hash
containing the chromosome, coordinate, variant, and unique ID of each variant. Each
entry in dbSNP is examined and compared to the hash. If there is a match at the same
chromosome, coordinate, and variant then the variant is annotated with the appropriate
rsID. This task is made more difficult as each coordinate in dbSNP can have multiple
variants. Additionally, dbSNP reports variants as if they were located on the positive
strand. Thus, if the strand is ‘-‘, the reverse complement of the variant must be compared
to the dbSNP entry. Again, if no rsID is found, a ‘-‘ is annotated as a placeholder. There
is no more annotation to perform at this point. The array is returned to the main script and
written to a file which will be imported by Java code to be viewed in the CLC-Bio
Workbench.
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3.2.1.9

FilterOutputData.pl

The user may request that output contain variants on only the positive strand, negative
strand, or both. Additionally, the user may request that only donor sites, acceptor sites,
cryptic sites, or natural sites be displayed. This script accesses those preferences as
command-line arguments and eliminates variants matching the request criteria from the
file to be imported to the Workbench.

3.3 CLC-Bio integration
The CLC-Bio Genomics Workbench is a commercial workspace for genomics research
(www.clcbio.com). Files are not generally used in this workspace, instead files are
imported as ClcObjects (objects). These objects represent specific biological data and are
associated with appropriate editors, viewers, and other object types. The Workbench is
also a host to third-party applications (plugins) generally implemented using pure Java.
As the Shannon pipeline was coded in C and Perl, a Java-based connection to the CLC
environment was required. Additionally, as run-time is a paramount concern for the
pipeline given the number of variants it examines simultaneously, the existing C libraries
could not be converted to Java while maintaining necessary execution speed. Thus, I
designed the Java code not only to communicate with the CLC-Bio Workbench, but also
with the Perl and C code on the command-line.

3.3.1 Java classes
The CLC-Bio application programming interface (API) contains classes which smooth
integration of Java code with their system and provide additional bioinformatics-related
functionality. I developed a total of 16 classes in Java (Table 1) to provide functionality
including object importers, a wizard to allow users to input pipeline preferences, help
screens, a bridge between Java and command-line code, and additional miscellaneous
classes. Some classes are very short and required very little modification from example
code provided on the CLC-Bio developer’s website (connection.clcdeveloper.com).
These classes will not be described as they are straightforward to code and are necessary
for all plugins.
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3.3.1.1

Importing variant data

VCF is the standard format used by researchers and industry to store variants. It was
necessary that I develop a Java class to import VCF files into a format compatible with
the CLC-Bio Workbench. To reduce the degree to which error handling within the
command-line portion of the plugin is required, checks are performed during the import
process to ensure proper variant formatting. Although VCF files can contain a great deal
of data for each variant, the Shannon pipeline requires only 5 fields of ≥ 9 potential fields
in VCF. These fields are: 1) the chromosome within which the variant is located
(CHROM), 2) genomic coordinates of the variant (POS), 3) a unique variant identifier
(ID), 4) the reference nucleotide at the genomic coordinates specified (REF), and 5) the
nucleotide observed at that position as a result of variation (ALT). VCF files are read
entirely into memory and examined line by line (one variant on each line) to ensure
proper formatting. First, the CHROM column is examined to ensure the chromosome
specified is a valid chromosome. Valid chromosomes include {1…22,X,Y, human
alternate locus/patch information for GRCh37.p11}. Preceding letters such as “Chr”,
“chr”, or “ch” are removed and if the remaining chromosome field matches a valid
chromosome, CHROM is valid. Genomic coordinate must be an integer within valid
chromosome lengths for the chromosome specified. In several instances, hg18
chromosomes are longer than their hg19 counterparts. The Shannon pipeline accepts data
using either hg18 or hg19 coordinates, however at the time of import the genome build is
unknown. Therefore, a valid genomics coordinate is defined as 0 ≤ valid coordinate ≤
max(hg18 chromosome length, hg19 chromosome length). The ID column does not have
to be examined as any input is valid. However, to ensure it is a unique identifier “-#” is
appended to each variant ID, where # is the line number of the VCF file. The REF field
must contain a single valid nucleotide. Multiple REF nucleotides imply an indel, the
contribution of which the Shannon pipeline cannot currently predict. Multiple ALT
nucleotides split the variant into multiple separate variants with single REF and ALT
nucleotides. Valid variants are stored in a tabular format object in the CLC-Bio
Workbench environment named “[name of VCF file][timestamp]”. Those variants which
fail any of these formatting requirements are stored in an object “[name of VCF
file]_InvalidVariants” with appropriate error messages appended to each variant.
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Table 1. Shannon pipeline Java class list and brief descriptions
Package

Significant
modification
required

LaunchPipelineAlgo

Base



Executes Shannon pipeline commandline code and imports results.

LaunchPipelineParameters

Base



Allows wizard parameters to be
accessed by LaunchPipelineAlgo

VCFImport

Base



Imports VCF files as GeneralClcTabular

PlotImportDeltaRi

Base



Imports Shannon pipeline results and
creates ΔRi plot objects.

PlotImportFinalRi

Base



Imports Shannon pipeline results and
creates Ri plot objects

PipelineOutputClcTabularImport

Base



Imports Shannon pipeline command-line
results as GeneralClcTabular

VariantClcTabularImport

Base



Imports variants in ‘Shannon Basic
Format’ as GeneralClcTabular

CommandLineExecutor

Base

InitClient

Client



Creates a folder in the Workbench
containing sample imported variants

LaunchPipelineRemoteAlgoAction

Client



Creates instance of LaunchPipelineAlgo
and launches preferences wizard

LaunchPipelineView

Client



Creates layout of wizard screen three
and sends user preferences to
LaunchPipelineParameters

PipelineActionGroup

Client

Specify Shannon pipeline icon and add
Shannon pipeline launcher to the
Workbench toolbox

LaunchPipelineCommand

Server

Creates instance of LaunchPipelineAlgo
to run on server machine

Class name

Brief description

Creates and executes a command-line
process

21

A second import class I developed which imports variants in the format [chromosome #]
[unique identifier] [coordinate] [reference/variant] will not be described in detail. All
formatting checks use the same methods as described in the VCF import class. This class
was devised primarily for testing in the early stages of pipeline development.

3.3.1.2

Manhattan-style plot importer

Visual representations of data allow overall trends to be observed and individual outliers
to be easily identified. CLC-Bio’s API provides a class for this purpose named
MAScatterPlot. My task was to prepare Shannon pipeline data for visualization as well as
create plots using MAScatterPlot. It is required that data points are sorted before plot
creation. I implemented a Quicksort algorithm to accomplish the sort. After sorting, data
are separated into an array representing the X axis of the plot and an array representing
the Y axis. MAScatterPlot allows tooltips to be displayed upon hovering the mouse
pointer over a data point. Tooltips contents include chromosome, coordinate, ΔRi, Ri after
variant contribution, and rsID (if available). Separate plots are created to visualize both
ΔRi and final Ri for each chromosome {1..22,X,Y} as well as a genome-wide plot. Thus,
if variants are present on all chromosomes a total of 50 plots are generated.

3.3.1.3

Tabular results importer

All Shannon pipeline results are imported and displayed in tabular format. Results
generated during command-line execution are recorded in a tab delimited file. The
tabular import class functions similarly to the variant importer. The Shannon pipeline
results file is read into memory and examined line by line and data are reordered and
formatted. Column headers are named as well as the resulting tables.
Variants are split into four separate tables. ‘Complete Variant Information’ contains all
variants. ‘Inactivating Variant Information’ and ‘Leaky Variant Information’ contain
variants predicted to be inactivating or leaky respectively. ‘Cryptic Variant Information’
contains all variants located within cryptic splice sites. Column headers in Inactivating
Variant Information and Leaky Variant Information tables are Chromosome, Coordinate
(of splice site), Strand, Ri-initial, Ri-final, ΔRi, Type (donor or acceptor), Gene Name,
Location (natural site or cryptic site), Input Coodinate (of variant), Input Variant, and
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Input ID (unique variant ID). There are additional column headers in the Complete
Variant Information and Cryptic Variant Information tables which are Location Type
(intronic or exonic), Loc. Rel. to Exon (cryptic site is 5′-flanking or 3′-flanking compared
to the nearest exon), Dist. From nearest nat. site, Loc. of nearest nat. site (coordinate of
nearest natural site), Ri of Nearest Nat. Site, Cryptic Ri relative to nat. (greater or less),
rsID if Available, and Average Heterozygosity (if rsID is available).
Columns containing real numbers are rounded to two decimal places. Strand is
represented as ‘0’ or ‘1’ in Shannon pipeline results and is converted to ‘+’ or ‘-‘
respectively. Some columns may have fields which contain no data such as Loc. Rel. to
Exon if a nearby natural site is not found. In these cases the entry is filled with a null
value to allow automatic sorting. By default, ClcGeneralTabular sorts columns when the
header is clicked. To function intuitively, columns must contain only a single type of data
or null values. If more than one type of data are present, sorting will default to
lexicographical order.

3.3.1.4

User preferences

I created a wizard built upon CLC-Bio’s class ClcWizardStepView. The first screen of
the wizard is created entirely by CLC-Bio and determines whether the Shannon pipeline
should run on a client (local computer), server, or grid system. The second and fourth
screens through which the user selects the location of Shannon pipeline input and where
to save Shannon pipeline results are also generated by CLC-Bio. I have restricted the
object types which may be used as Shannon pipeline input to GeneralClcTabular objects.
This object type is generated by the import classes discussed in 3.3.1.1.
I created the third wizard screen (Figure 3) using Java Swing. A JComboBox allows the
user to indicate which genome build is appropriate. Variants are represented in hg18 or
hg19 coordinates. Four groups of three JRadioButtons are used to determine the
following: 1) In the types frame, donor, acceptors, or both may be displayed to the user
after pipeline execution. 2) cryptic sites, donor sites, or both types of sites may be
displayed. 3) In the ‘Output Format’ frame, the user can opt to create delta Ri plots, final
Ri plots, or both. 4) The user can opt to view output containing one or both strands. By
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default, the selections made are hg19, show donors and acceptors, show cryptic and
natural sites, show both types of plots, and show both strands. Choices made at this step
are recorded using the class LaunchPipelineParameters which extends CLC-Bio’s class
AlgoParametersInterpreter. I tailored functions in the class to accept the specific choices
users are offered. This class allows parameters to be accessed by the LaunchPipelineAlgo
class (discussed in 3.3.1.6).

3.3.1.5

Ensembl, and dbSNP, and human genome distributions

Four large databases are required for variant annotation and Ri prediction. Ensembl Gene
66 contains information needed for gene annotation. The Single Nucleotide
Polymorphism Database 130/135 (dbSNP) is used to determine if a variant is novel. Two
full reference genomes (hg18, hg19) in FASTA format are also required to examine
variants on each respective genome build.
As CLC-Bio requires that a plugin can run with no internet connection, it was necessary
to package the databases for release. In the initial stages of plugin development I
attempted to package the necessary databases along with the plugin itself. However, this
would have made updating the plugin difficult and would result in very large downloads
for users every update. It was decided – with input from CLC-Bio – to instead package
the databases in separate plugins. By employing this method, database plugins can be
downloaded once by the user and any subsequent updates to the main plugin can be
downloaded separately. This solution also lends itself to future updates of the reference
genome versions and associated annotations, and the development of applications that
enable mutation analysis in non-human genomes.
I created two additional plugins containing these databases. The first plugin contains
hg18 FASTA files, dbSNP 130, and Ensembl Gene 66 (a ‘lift-over’ was performed to
transform genomic coordinates to hg18). A second plugin was created which contains
hg19 FASTA files, dbSNP 135, and Ensembl Gene 66. During execution of the main
plugin, a check is performed that confirms the required database plugin is also installed.
If the plugin has not been installed, main execution will halt and a message will be
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Figure 3. Shannon pipeline genome build, filtering, and display options.
This is a screenshot of the third wizard screen after selecting ‘Launch Pipeline’. By
default, the displayed choices are selected. Genome build may be hg18 or hg19. In the
types frame, donor, acceptors, or both may be displayed to the user after pipeline
execution. Similarly, cryptic sites, donor sites, or both types of sites may be displayed. In
the ‘Output Format’ frame, the user can opt to view delta Ri plots, final Ri plots, or both.
The user can opt to view tabular and plot output containing one or both strands.
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displayed to the user (and in the error log), informing them that the appropriate database
plugin must be installed.

3.3.1.6

LaunchPipelineAlgo class and the command-line

Development of this class required the creation of Perl code as well. Specifics of the
necessary Perl scripts can be found in 3.2.1.1 and 3.2.1.2. The overall workflow of a
Shannon pipeline execution from the Workbench is as follows: 1) Variants are imported
using importer classes described in 3.3.1.1. 2) The user selects preferences using a wizard
which are recorded using the LaunchPipelineParameters class and LaunchPipelineAlgo
reads these parameters. 3) Perl and C code is automatically installed if necessary. 4) A
parameters file is created and the command-line portion of the Shannon pipeline is
executed taking these preferences into account. 5) Shannon pipeline results are imported.
6) Imported Shannon pipeline results (objects) can be viewed in standard CLC-Bio
editors. The class LaunchPipelineAlgo is involved in steps 2-5.
Shannon pipeline C libraries must be installed before execution. Previously, a collection
of Perl wrappers were designed to allow Perl code to make use of the C libraries. As a
result of this interconnectivity, releasing compiled code would require separate
distributions not only for different architectures (Linux 64bit, Linux 32bit, etc.) but also
for different versions of Perl. Additionally, Perl Makefiles produce different executables
based on whether the Perl installation used to created them is ‘threaded’ or ‘nonthreaded’. Based on this variability, the choice was made to compile the code
automatically on each machine. I created a Perl script that checks to see if libraries have
been previously installed, and if not, creates a Perl Makefile and runs ‘make’ and ‘make
install’ to install them. Additionally, standard output and standard error streams are
redirected to files that can be viewed from the CLC-Bio Workbench in the case of error.
LaunchPipelineAlgo executes this Perl script and waits to receive its return code. If the
installation was unsuccessful, a non-zero code is returned. In particular, error code 100 is
returned in the case of an unsuccessful installation. In this case, execution halts and “C
library installation unsuccessful” is appended to the Shannon pipeline execution log. The
libraries may have to be installed manually in this case. Otherwise, if the libraries are
already installed or were installed successfully, execution continues. Library installation
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has been tested on the following system configurations: Perl 5.8.8, 5.10.1, 5.12.3, 5.14.2,
GCC 4.1.2, 4.2.1, 4.4.3, 4.6.3, Ubuntu 2.6.32, CentOS 2.6.18, Fedora 3.1.0-7, Mac OS X
(Lion) 10.7.4.
A parameters file is created which can be accessed by the command-line portion of the
Shannon pipeline. This file contains both user preferences and hard-coded settings for the
pipeline. These parameters include the human genome version, Ensembl version, dbSNP
version, distance from a modified cryptic site to attempt to locate a natural site, maximum
distance a cryptic site can be from a natural site to display comparisons between them,
the locations of Ensembl Gene 66, dbSNP 130/135, hg18, hg19, and splice site
information weight matrices. The parameters file is placed in the directory containing
command-line Shannon pipeline code.
After Shannon pipeline results are generated by the command-line code, results must be
imported. Previously described tabular and plot import classes are invoked to accomplish
this task. Standard output and standard error files are imported simply as ClcStrings. If
any import is unsuccessful, execution will continue but a note will be made in the log
describing the nature of the failure.

3.3.1.7

Help documentation

I implemented a series of help screens using JavaHelp. Help is accessed through a
question mark on the bottom left of the preferences wizard (can be seen in Figure 3). An
electronic

version

of

help

screens

can

be

found

online

at

http://www.clcbio.com/files/usermanuals/shannon_pipeline.pdf. Help sections include
Quick Start, Tables, Plots, Tracks, FAQ, and requirements. In the online version, an
additional section describing plugin installation is included.

3.3.1.8

Client-Server architecture and distributions

As documented in Table 1, three packages of Java classes form the basis of the clientserver architecture of the Shannon pipeline. The base package is shared by both the client
and server packages. This style avoids code duplication across client and server packages.
Client and server distributions are created using Apache Ant (Ant). The client distribution
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can be built in two different formats. The first format contains Perl and C command-line
based code while it is removed in the other format. This results in a one client distribution
which can be run independently from a server (standalone) and one which serves only as
a front end for the server distribution (dependent). The dependent distribution is
beneficial for those users running a client computer which does not meet the
requirements to run the Shannon pipeline. The standalone distribution offers greater
flexibility and allows pipeline execution on either the client or server machines.
I encountered several hurdles while attempting to create a standalone distribution. First,
CLC-Bio requires that only one copy of the program can be executed at a time for each
license a user has obtained. The Workbench has built-in functionality which disallows
multiple executions of the same plugin on either the workbench or server. However, this
functionality does not prevent a user from running the Shannon pipeline on their client
machine and a server machine at the same time. To prevent this, I added code within
LaunchPipelineAlgo which checks if the Shannon pipeline is already being executed on
the client or server machines. If the pipeline is being executed in one location, submitting
a job to the other is disallowed and an error message is displayed to the user.
Distributions created through Ant are sent to CLC-Bio where they are encoded and
posted on their website and within the Workbench plugin section for download. C files
are encrypted independently from CLC-Bio using openssl. Upon a signal from
LaunchPipelineAlgo, if C libraries are not already installed they are decrypted, compiled,
and the source is deleted. To use the Shannon pipeline, a user must enter a license key
provided by CLC-Bio. In total, 5 distributions currently exist for download: 1) Shannon
pipeline server 2) Shannon pipeline client (standalone) 3) Shannon pipeline client
(dependent) 4) hg18 databases 5) hg19 databases. Uninstallation is accomplished through
the plugin widget in the Workbench. In the case of hg18 and hg19 database plugins,
databases are deleted upon uninstallation.
Early Shannon pipeline implementations did not run on Mac OS X. I made several minor
modifications to support Mac execution. First, many OS X directories contain spaces. I
updated the CommandLineExecutor class to submit command-line processes correctly if
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spaces are present by submitting the command as an array. Doing this specifies where
spaces in the command are by placing space delimited elements into the array. Spaces
present in any single element of the array are automatically escaped properly. Secondly,
most OS X distributions do not include GCC by default. GCC is required to compile the
C libraries. Users must manually download either Xcode or other software containing
GCC to be able to compile the libraries. This requirement is specified in the Shannon
pipeline documentation.

3.4 Performance of the Shannon pipeline software
The unique identifier present in both the VCF or tab-delimited format serves several
purposes. Input data may be stored in a hash allowing efficient annotation of individual
variants or those originating from multiple exome or genome sequences. Given the
minimum overhead from chromosome processing incurred to process each individual
chromosome present in the input data (~1 hour if all chromosomes present in input file).
This startup time is based largely on the annotation process. Unique identifiers allow
input to be combined, thus reducing total run-time and required user interaction.
To assess performance, all point mutations detected in the complete genomes of the three
cancer cell lines were analyzed using the pipeline. Variants in the cell lines U2OS
(osteosarcoma-derived), A431 (epidermoid squamous carcinoma-derived) and U251
(glioblastoma-derived) were examined and filtered to create tractable sets of variants.
Predicted splice-altering mutations not found in dbSNP135 (a list of ~54 million known
nucleotide polymorphisms) and those with less than 1% average heterozygosity are
reported (Appendix A).
The Shannon pipeline processes SNVs to identify and annotate splicing mutations with
sufficient speed to analyze single or multiple genomes within a few hours. Analysis of all
single nucleotide substitutions detected in the genome of the U2OS cell line (211,049
variants) is completed in 1 hour 12 minutes on an I7-based CPU in either Linux or Mac
OS X (Table 2). The speed analysis is dependent on the number of chromosomes
represented in the input data. The state machine facilitates the analysis of all variants on a
single chromosome with the highest efficiency because genomic data for each
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chromosome must be read and parsed. A complete analysis of 300 variants on a single
small chromosome (e.g., chromosome 22) can be completed in 5 minutes. Variants
distributed throughout all chromosomes require at least one hour to process. The Shannon
pipeline should be executed on a machine with sufficient RAM to store the largest human
chromosomes in memory with each base requiring 17 bytes of memory (≥ 4 gigabytes).
When all chromosomes are represented, increasing the number of mutations results in an
approximately linear increase in actual computation time, after accounting for the
overhead required for memory management of genome sequences and annotations. For
example, 2 hours 35 minutes is required to analyse 1,872,893 sequence variants from the
most

recent

data

release

on

the

Exome

Variant

Server

(http://evs.gs.washington.edu/EVS/).
Increased speed comes at the expense of diminished ability to analyze complex mutations
on the fly, such as insertions and deletions or multinucleotide substitutions. Such
variation is significantly less common than SNPs in wildtype genome and exome
sequences
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, but nevertheless can have consequences on gene function and phenotype.

The ASSA server is capable of analyzing these categories of mutations; however it is
considerably slower than the Shannon pipeline (30s per variant). In the future, the
Shannon pipeline will be integrated with the ASSA server to examine complex variants
seamlessly.
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Table 2. Performance of Shannon Pipeline for mRNA splicing mutation prediction
Source of variants

Number of variants analyzed

Running time*

U2OS cell line

211,049

1h 12m

A431 cell line

290,589

1h 17m

U251 cell line

314,637

1h 20m

ESP 6500 Exomes

1,872,893

2h 35m

Note *Intel I7 CPU with 16 Gb RAM
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4 Shannon pipeline - Results
4.1 Stratification of variants
Similar to ASSA, the pipeline analysis produces summary tables for different types of
mutations (assuming each type is represented): 1) complete sets of all splicing variants, 2)
mutations predicted to inactivate splice sites, 3) leaky splicing mutations that reduce but
do not abolish splicing and 4) cryptic splice sites that are either activated, inactivated or
reduced in strength. Inactivating variants are defined as those that reduce the Ri of the
affected binding site below 1.6 bits
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. Binding sites containing a leaky variant are

defined as those, in which initial Ri is decreased upon mutation to Ri > 1.6. Finally,
candidate cryptic sites encompass all sites with higher affinity for binding than a
corresponding natural site based on comparison of their respective Ri values. Tabular data
can be sorted by clicking the column header of each column. Data can be exported and
viewed without modification in a spreadsheet program using CLC-Bio’s built in export
functionality.
The 5′ end of the first exon and the 3′ end of the last exon of a gene are not splice sites.
They instead form the boundary of the gene. Therefore, the Shannon pipeline does not
report mutations that affect their ∆Ri at these positions; the exception being genes that
encode alternate splice forms using further upstream/downstream exons present in
Ensembl 66. Variants which alter the strength of cryptic splice sites within the first and
last exons are also considered. Use of a strengthened cryptic donor in the first exon or
acceptor in the last exon could lead to a truncated exon. The Shannon pipeline considers
the exonic cryptic sites of the opposite polarity (acceptors in first exons and donors for
last exons), as their activation could potentially - but rarely - lead to the formation of a
cryptic intron within these exons if a second pre-existing cryptic site of opposite polarity
is present in the proper orientation.
Although Shannon pipeline output contains a vastly reduced number of potentially
significant variants, further manual filtering is necessary to obtain the final set of
functionally relevant sites. Pipeline output is generated for all variants that result in ∆Ri >
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±1 bit. One bit corresponds to an approximately 2 fold difference in binding affinity,
which is the limit of detection of fold change by quantitative real-time polymerase chain
reaction (qPCR)

39

. The user then filters out those variants least likely to be functionally

relevant. For example, a natural site that has experienced an increase in information
content will generally not be of interest. The increase will likely only serve to widen the
existing gap in Ri between the natural and nearby cryptic sites. Thus, it is recommended
those natural sites with positive ∆Ri values as well as cryptic sites with reductions in Ri
value be removed. Pipeline generated annotations that are found in the tabular output help
simplify the data filtering process. As discussed, tabular results are displayed in separate
tables used to distinguish natural and cryptic splicing mutations. Recommended filters
used for cryptic splicing mutations are based on criteria given in 34 (a) ∆Ri > 0, (b) cryptic
site is located within an exon or within an intron less than 300 bp from nearest natural
site, (c) cryptic splice site Ri value exceeds the strength of the nearest natural site Ri of the
same type and (d) intronic cryptic splice sites are selected 5′ to the exon if acceptors and
3′ to the exon, if donors. All reported variants are further categorized according to
whether they had been previously reported or were novel by the Shannon pipeline. In
Table 3, only novel and known variants < 1% average heterozygosity in dbSNP are
reported. Variants < 1% average heterozygosity are more likely to be functionally
significant due to selection (deleterious variants are selected against). Nevertheless, any
threshold for filtering based on heterozygosity can be used by the user.

Filtering of cryptic splice sites exceeding the strength of and close to adjacent natural
sites of the same phase eliminates many predicted unused cryptic sites with changes in Ri
values. Finally, it is recommended that genes lacking HUGO-approved names or
encoding non-coding RNAs, and pseudogenes should be filtered out. The manual
filtering process (especially of cryptic splicing mutations) significantly enriches for likely
mutations in the genomes of these cancer cell lines by the order of 10,000 fold.

33

Table 3. Enrichment for predicted splicing mutations after processing and filtering

Cell

Initial variants

Novel

Novel

Natural site

Cryptic site

Overall

line

analyzed

Natural site

Cryptic site

(SNP)*

(SNP)*

Mutation
fraction

A431

290,589

16

13

13

3

0.015%

U251

314,637

7

10

18

3

0.012%

U2OS

211,049

22

9

13

4

0.022%

Total

816,275

45

32

44

10

0.016%

Note *dbSNP135; <1% heterozygosity; minor allele
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4.2 Displaying results
Ri and final Ri values are plotted by chromosome location, similar to Manhattan-style
representations, for either individual chromosomes or entire genomes. Hovering the
cursor over data points generates tooltips containing information needed to find the
complete entry within the corresponding tabular data. To locate interesting data points, a
zoom function allows closer inspection of the plot. This visualization allows patterns to
be observed and data points which stand out to be easily located and inspected more
closely in tabular format or on the ASSA server.
Chromosome-specific, custom browser tracks indicating ∆Ri values in BED format are
also generated. This enables visualization of predicted mutations in the context of other
genome annotations, for example, mapped reads from RNA-seq, spliced expressed
sequence tags (ESTs) and known mRNAs. Figure 4 depicts three methods of displaying
Shannon pipeline results.

4.3 Validation with RNA-seq expression data
RNA-seq analysis using published data from these cell lines
Shannon pipeline results with expression data. TopHat
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40

was used to compare

was executed with the

following command-line options: -g 5 --solexa1.3-quals -p 8, and examined with the
Integrative Genomics viewer (IGV)
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to interrogate predictions made with the Shannon

pipeline.
Several variants detected in genomes of U2OS, U251 and A431, which were predicted to
affect splicing, were compared to the distribution of RNA-seq reads in their respective
regions of the transcriptome. When interpreting these data, it is assumed that predicted
mutations are present in a genetic background, in which the other parentally derived
allele lacks the same variant (i.e., heterozygous). Abnormal reads or exon skipping of the
mutant allele is viewed in the context of a single allele and expected normal splicing of
the corresponding exon. For mutations that are predicted to inactivate a splice site, it is
assumed that a binomial distribution in the number of expected reads is present, based on
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Figure 4. Twelve DNA sequences and their corresponding information changes.
The Shannon pipeline software generates the following types of output. A. Tabular
results showing the first 12 of 134 changes in Ri values at different genomic coordinates
predicted to be significant, after filtering for cryptic splicing mutations from all variants
(n=22,197) in a complete genome sequence. The first filter eliminates exonic cryptic
sites, the second selects cryptic sites with increased Ri values, the third ensures that the
cryptic site is stronger than the corresponding natural site of the same phase and the final
filter ensures that all remaining sites exceed the minimum Ri value of a functional splice
site. B. Manhattan-like plot indicating the locations and changes in Ri of all variants
which alter splice site information in a region within intron 1 of BRCA1
(chr17:41277500-41288500) from different individuals with increased breast cancer risk.
C. Custom track illustrating a cryptic splicing mutation detected in an ovarian serous
carcinoma that inactivates the acceptor site of exon 4 in STXBP4, resulting in the
activation a pre-existing, in frame, alternative splice site 6 nucleotides downstream.
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the wild type allele. Natural splice site mutations are expected to significantly reduce the
number of splice junction-spanning reads in relative to those in the adjacent exons,
consistent with exon skipping. In some cases, intron inclusion adjacent to a splice site
variant with lower Ri value may also be evidence of a splicing mutation. In U2OS, 10 of
13 novel inactivating variants found in mutated natural splice sites met these criteria,
along with an additional 2 probable mutations (Appendix A, Table S1). The same criteria
were met by 2 of 4 (with 1 additional probable) novel inactivating variants in U251
(Appendix A, Table S2), and 4 of 7 (with 1 additional probable) variants in A431
(Appendix A, Table S3).
Shannon pipeline predictions were supported by expression data for 1 of 7 activated
cryptic site variants in U2OS, 1 of 14 variants in A431 and 0 of 10 in U251. Many of the
predicted splice sites reside in intronic regions or alternative exons that map far upstream
or downstream of constitutively expressed exons. They are unlikely to displace
constitutive isoforms, since donor site recognition is processive
lengths of such cryptic exons would probably be suboptimal
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and the increased

. Often, these sites are

associated with rare, alternatively spliced ESTs expressed in other tissues than these cell
lines. Because these variants are often extra-exonic, changes in expression must be
inferred indirectly from decreased read count, intron inclusion or increased exon
skipping. Changes in reading frame from inclusion of out-of-phase intronic sequences
may induce nonsense-mediated decay (NMD). Reads mapping to adjacent introns are
expected to be reduced in number as a result of NMD. Sequencing reads that are
concentrated in the intronic region adjacent to exon of interest are considered support for
predicted mutations. NMD may also affect transcript read counts associated with severe
leaky or inactivated natural donor sites, which produce exon skipping with frameshifting. Several predicted splicing mutations confirmed by RNA-seq are well-known
driver mutations that contribute to tumor phenotypes.
Interesting results include a unique natural donor site mutation within RBBP8
(NM_203291.1:c.248G>A or chr18:20529676G>A; 6.2  3.2 bits [indicating the change
in the Ri value of the donor site, before and after it is mutated]) in A431, a tumour
suppressor gene mutated in numerous neoplasias with a role in endonucleolytic
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processing of a covalent topoisomerase-DNA complexes. The mutation weakens but does
not abolish the natural donor site from 6.2 to 3.2 bits. A cryptic mRNA splice form using
a pre-existing donor site 24bp downstream to the weakened natural site is confirmed by
RNA-seq (Figure 5A). The ASSA server predicts the activation of this intronic cryptic
donor site, as well as a second site of equal strength further downstream to the mutated
donor site (Figure 5B). There are a total of 56 reads that both encroach into the intron
and overlap this variant. Forty-one of these cover the cryptic exon splice junction of
interest (the aligned reads stop at the 3.2 bit cryptic site, which is 24 nt downstream of the
natural site, and continue into the next natural exon). Thirty-one junction spanning reads
also contain the A-allele. There are an additional 23 reads that cross into the intron, but
do not extend as far as the cryptic site of interest. In 19 cases, these reads contain the Aallele. The remaining 4 intron-crossing reads which contain the G-allele appear to be
misaligned, as they contain short matches (≤ 3 nt) to the downstream exon. There are an
additional 2 reads that span the junction between the downstream cryptic exon junction
and the adjacent exon (31 nt downstream; also 3.2 bits). Finally, 12 reads are correctly
spliced and contain the mutant A-allele, suggesting that the natural site is not completely
inactivated by this nucleotide substitution, which is consistent with leaky splicing.
Changes in expression are also noted in other genes. DDX11 is inactivated in U2OS
(chr12:31242087T>G; 6.89  11.73 bits). DDX11 is a component of the cohesin
complex which has a crucial role in chromosome segregation, and is essential for survival
of advanced melanoma 45. In U2OS, WWOX, a tumor suppressor gene in osteosarcoma 46,
contains a leaky mutation (chr16:78312497C>A; 10.24  6.67 bits). Both alleles of
APIP, an apoptosis associated gene, are inactivated in U251 (chr11:34905054G>C; 9.32
 0.54 bits). Gene expression of APIP is down regulated in non-small cell lung
carcinoma
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. Amplification of METTL2B, which harbors a leaky mutation in U251

(chr7:128117227G>A; 5.48  2.47 bits), has been demonstrated in several cancers,
including glioblastoma
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. In A431, leaky mutations are also confirmed in the

glioblastoma-initiating gene TRRAP (chr7:98533187T>G; 9.09  7.16 bits;

49

) and

USF1 (chr1:161013165G>T; 4.89  3.59 bits), which encodes a transcription regulator
important for TGFβ2 expression in glioblastoma 50. SYNE2, which is mutated in a
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Figure 5. Predicted mutation splicing phenotype supported by RNA-seq
Predicted RBBP8 splicing mutation, chr18:20529676G>A (NM_203291.1: c.248G>A), is related
to transcripts mapped to this region. A. IVG genome browser display of read distribution at the
exon 4/intron 4 junction. Green boxes within the vertical hashed lines indicate the presence of the
A allele. B. The natural and cryptic splice sites illustrated by sequence walkers generated on the
ASSA server. The arrow tail and head draw attention to the location and sequence of the
reference and variant sequence. The mutation reduces the strength of the natural donor site from
6.2 to 3.2 bits. All but 3 of the 59 reads extending into the intron contain the variant allele, as
indicated by the green positions within the reads. These reads extend into the exon and terminate
at the closest intronic cryptic donor site (chr18:20529700). The mutated natural and cryptic sites
are of equal strength, which explains splicing at both sites.
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significant percentage of head and neck squamous cell carcinomas
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, contains an

inactivating splice site variant in A431 (chr14:64669514T>A; 1.89  0.83 bits).
RRM2B, an inducible DNA repair gene that has been implicated in squamous cell
carcinoma
15.02
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, contains an inactivating mutation in A431 (chr8:103250667A>C; 3.6 

bits). SMARCD1, encoding a chromatin modulator that interacts with nuclear

receptor transcription factors, is also inactivated in A431 (chr12:50480538G>C; 8.46 
3.21

bits), and has been shown to be mutated in hepato- and other carcinomas 53.

Several mutations were found in potential tumor-associated genes, with either suggestive
or little supporting expression data. However, defects in many of these genes have been
implicated in various neoplasias including glioblastoma, osteosarcoma, and epidermoid
squamous carcinoma. In general, these were predicted leaky mutations, where effects
(diminished read counts and exon skipping) were inferred against the confounding
background of a presumably intact allele. Natural site mutations in FANCD2
(NM_033084.3:c.3106-9T>A; 6.0  3.5 bits; delayed activation of the DNA damage
response in gliomas
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) and MDC1 (NM_014641.2:c.2129-8G>C; 6.4  4.7 bits;

mediator of the DNA damage checkpoint and underexpressed in many cancers
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) were

found in the U251 cells.

4.4 Characterization of defective pathways
Potential driver mutations affecting protein coding of genes from the A431, U2OS, and
U251 cell lines have recently been reported

40

. Functionally significant driver mutations

affecting splicing are expected to comprise many of the same pathways implicated by
protein coding mutations that are predicted to be damaging. The gene set with combined
driver point and copy number alteration was examined using Reactome
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. Shannon

pipeline results, supported by RNA-seq data, were added to gene sets proposed by 40 and
the expanded gene set was examined with the overrepresentation analysis tool in
Reactome. Of the genes containing transcript-validated splicing mutations, both datasets
were consistent in 2 of 5 pathways in A431 (interferon signaling and cytokine signaling
in immune system), 8 of 8 pathways in U2OS (cell cycle mitotic, cell cycle, DNA
replication, mitotic M-M/G1 phases, M phase, kinetochore capture of astral microtubules,
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mitotic prometaphase and apoptosis) and 0 of 2 pathways in U251. Affected pathways
and relevant genes can be found in Table 4. The gene set including all inactivating and
leaky variants (regardless of verification status) were found in 5 of 7 of the same
pathways in A431 (additionally, a variant was found in the semaphorin interaction
pathway), 8 of 12 of the same pathways in U2OS and 0 of 11 pathways in U251. In A431
and U2OS, these splicing mutation predictions enhance and strengthen the pathway
analysis based on protein coding mutations alone.
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Table 4. Enriched pathways containing genes predicted by the Shannon pipeline
Cell line
A431

U2OS

RANBP2, EIF4A2, NUP98

Additional gene in
pathway predicted by
the Shannon pipeline
PIAS1

RANBP2, EIF4A2, NUP98

PIAS1

Genes from
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in pathway

RRM2, ZWINT, PLK1, PSMC3,
AURKB, PKMYT1, TYMS, POLD2,
CCNB2, MCM3, MCM5, UBE2C,
CCNE2, KIF23, NEDD1, PRIM2,
PSMD13, TUBA3D, MCM7, ERCC6L
RRM2, ZWINT, PLK1, PSMC3,
AURKB, PKMYT1, TYMS, POLD2,
CCNB2, MCM3, MCM5, UBE2C,
CCNE2, KIF23, NEDD1, PRIM2,
PSMD13, TUBA3D, MCM7, ERCC6L
POLD2, MCM3, CCNB2, ZWINT,
MCM5, PSMD13, PRIM2, PLK1,
KIF23, TUBA3D, PSMC3, AURKB,
MCM7, ERCC6L
MCM3, CCNB2, ZWINT, MCM5,
PSMD13, PRIM2, PLK1, KIF23,
TUBA3D, PSMC3, AURKB, MCM7,
ERCC6L
CCNB2, ZWINT, PLK1, KIF23,
ERCC6L, TUBA3D, AURKB
ZWINT, PLK1, ERCC6L, TUBA3D,
AURKB
ZWINT, PLK1, ERCC6L, TUBA3D,
AURKB
CAD, PSMD13, PSMC3

Pathway name
Interferon signaling
Cytokine signaling in
immune system

CENPN

Cell cycle

CENPN

Cell cycle, mitotic

CENPN

DNA replication

CENPN

Mitotic M-M/G1 phases

CENPN

M phase

CENPN

Kinetochore capture of
astral microtubules

CENPN

Mitotic prometaphase

CTNNB1

Apoptosis
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5 Discussion
Complete genome and exome sequencing detects numerous rare, non-recurrent mutations
in different individuals with the same disease diagnosis. Making sense of genetically
heterogeneous results requires detection and interpretation of mutations in many
genomes. The identification of significant mutations in different driver genes, followed
by a gene set or pathway analysis can reveal common, essential pathways in otherwise
genetically heterogeneous diseases, such as cancer. Incomplete detection or
reclassification of coding mutations will most likely impact the sensitivity of these
analyses. Most existing methods to predict the effects of splice site variation lack
scalability, transparency or portability, with respect to their scoring systems. Information
content can be applied to any region of any adequately annotated genome. Change in
information (Ri) is a portable measure and its thermodynamic basis meaningfully
estimates the effects of splicing variation. By contrast, other systems (e.g.,
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) are not

suited for genome scale analysis and produce results that are not directly related to splice
site strength.
A recent study reported the genomic, transcriptomic and protein sequences in the cell
lines that were the source of the data that I analyzed
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. It described the same single

splicing mutation in the APIP gene identified in the present study, but none of the others
that predicted by the Shannon pipeline. Further, there was no overlap between the genes
containing predicted protein coding mutations in

40

and those indicated from the current

study. This was somewhat surprising, it was anticipated that some loss of function
mutations in tumor suppressor genes would arise from compound heterozygosity. Instead,
mutant genes from both studies tended to occur in the same pathways (for U2OS and
A431).
Many of the predictions made by the Shannon pipeline were supported by the same
RNA-seq data that identified only APIP

40

. Conventional splice junction mutation

analysis of NGS data, which tends to emphasize only the significance of changes in
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conserved splice junction, intronic dinucleotides does not appear to be as sensitive or
comprehensive as the information-based Shannon pipeline 7. Assuming the cell line
genotypes faithfully reflect the tumor genetics, likely driver mutations in the tumors were
missed. These genes contribute to the tumor signatures and in most instances, belong to
major pathways that are dysfunctional in the tumor. A caveat is that many of these
cancer-associated genes have been uncovered in other tumor types, rather than the tumors
that gave rise to the cell lines studied here.
Many of the predicted mutations that are supported by expression data make sense in
light of independent studies, which have suggested the same driver genes and pathways
that are defective in these tumor types

51,58-60

. Note that the recommended filtering

procedures eliminate and/or minimize inclusion of mutations in gene classes with no
known connection to cancer disease etiology. The sensitivity and specificity of these
predictions support use of the Shannon pipeline in other somatic genomic analyses, and
possibly for a wider spectrum of heritable genetic disorders.
The interpretation of potential splicing mutations in complete genome data is also
challenging because the source of annotations, Ensembl, contains many accurate but
apparently irrelevant genomic features. These comprise exons called on the basis of a
single or a few ESTs with deep intronic locations (relative to constitutive exons) 61,62, and
predicted mutant ESTs that are in fact present in non- or low expression genes (due to
tissue specificity of the gene). Such cases indicate that the predicted mutation acts only
upon these alternative splice forms, rather than the major transcript produced by the gene
containing this gene. Where the RNA-seq data are either insufficient or irrelevant,
pseudogenes (or genes which are members of families containing pseudogenes) may
contain mismapped reads for the non-functional copies that can produce false positive
mutation calls. Automatic filtering of genes from the RNA-seq data prior to validating
information-based predictions would significantly simplify post-hoc processing of the
Shannon pipeline. Until such a workflow is available, individual predicted mutations
have to be assessed manually, because cryptic sites that alter the strength of a “decoy”
exon, while a technically legitimate result, is probably irrelevant as a potential diseasecausing mutation.
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6 Conclusion and future development
Accurate genome-scale mutation analysis of bulk sequencing data in a timeframe suitable
for integration with prediction tools for other types of mutations will be needed to
discover disease-related genes and pathways in large-scale genomic studies of many
patients. The need to distinguish probable pathogenic from benign sequence changes has
become acute 63. Computing efficiency is essential for concurrent analysis of large sets of
genome sequences
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. As the volume of whole-genome next-generation sequencing data

continues to increase, variants of unknown significance are also likely to become more
common. The processing speed attained by the Shannon pipeline has distinct advantages
over existing software for identifying functional non-coding variants detected in large
multi-genomic analyses. The Shannon pipeline is not intended to replace laboratory
examination of variants, rather it is meant to reduce time and money spent examining
variants unlikely to be deleterious. In this way, researchers can use the pipeline to
pinpoint those variants most likely to be deleterious for further examination in the
laboratory. Thus far, the Shannon pipeline has been downloaded under an evaluation
license by more than 200 researchers and has been purchased by the US National Cancer
Institute. Some feedback has been received by researchers, in one case prompting me to
fix a bug in the VCF import class which caused the import to fail if a ‘?’ was present in
the VCF header.
There are many opportunities for future improvements to the Shannon pipeline, some of
which are already in the early stages of development: 1) I have begun converting Perl
code to C++. This transition will improve performance, allow Windows compatibility
without requiring specific versions of Perl (or any version of Perl), and facilitate the
ability to distribute compiled code. This offers many advantages including increased code
security and the removal of the requirement to download GCC or GCC equivalent on a
Mac or Windows. 2) CLC-Bio has recently implemented their own VCF importer and
exporter classes. This alleviates the need for the VCF importer I have developed and the
Shannon pipeline must be modified to become compatible with the new classes. 3) I have
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begun work on implementing a version of the Shannon pipeline used to analyze variants
in the mouse genome. Since the pipeline was built generically, theoretically the pipeline
can work on any sufficiently annotated genome with minor modifications. Work required
to examine different genomes using the pipeline requires modifications to Ensembl Gene
databases to make them compatible with the pipeline. 4) Implementation of indel
analysis. C libraries exist which perform this analysis, however new code must be
implemented to use those libraries and existing annotation code must be modified to
properly annotate indels. 5) Automatic integration of pathway analysis would alleviate
the need to manually use Reactome or other pathway analysis tools to examine pipeline
results. 6) A weight matrix exists for an intronic sequence necessary for splicing called
the branch point. The contribution of these sites are not observed in the current software,
but functionality to do so may be included in a future release. 7) The ability for the user
to submit a genome to act as the reference genome during calculation. In particular, this
upgrade would be important for cancer genome analysis which involves comparison of
variants present in a tumour against the reference sequence from normal DNA from the
same individual.
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Appendices
Appendix A: Shannon pipeline output for the U2OS, A431, and U251 cell lines.

Ri,final

ΔRi

Site

Gene

chr5:148630982G>A

10.04

7.03

-3.01

D

ABLIM3

Y

chr9:140507906C>G

9.45

6.83

-2.62

A

ARRDC1

LF

chr12:46355654A>C

7.66

5.61

-2.06

A

SCAF11

P

chr10:115470783A>C

8.72

6.80

-1.93

A

chr16:81060105T>G

3.99

2.87

-1.12

A

CENPN

Leaky

rsID

Ri,initial

Av. Hat.

Validated*

Table S1 Splicing mutations in cell line U2OS predicted by Shannon pipeline

Novel Variants

RP11-211N11.5.1

NE
Y

Known Variants < 1% Av. Het.
chr16:78312497C>A

10.24

6.67

-3.57

A

WWOX

rs8050128

0

Y

chr2:98177124T>G

7.96

4.70

-3.26

D

ANKRD36B

rs11681640

0

PS

chr5:78076488A>T

9.60

7.14

-2.45

A

ARSB

rs183651028

0

chr22:36657628T>G

8.94

6.88

-2.06

A

APOL1

rs41368549

0

N

chr2:32961745T>A

8.99

7.14

-1.85

A

TTC27

rs10200333

0

P

chr15:68445912T>A

16.57

14.72

-1.85

A

PIAS1

rs11633620

0.005

chr1:33318561T>C

5.86

4.55

-1.32

D

S100PBP

rs702836

0

N

chr17:73698557C>T

9.81

8.70

-1.12

A

SAP30BP

rs820232

0.009

Y

ΔRi

Site

Gene

chrX:91518144T>G

9.64

-8.99

-18.62

D

PCDH11X

NE

chr17:47286205A>C

9.57

-9.06

-18.62

D

GNGT2

Y

chr3:41277214G>A

8.87

-2.02

-10.88

A

CTNNB1

Y

Inactivating

rsID

Ri,final

Validated

H

Ri,initial

Av. Het.

Y

Novel Variants
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chr12:120613944A>C

8.78

-9.85

-18.62

D

GCN1L1

Y

chr3:52181002A>C

7.88

-10.75

-18.62

D

POC1A

Y

chr9:131133696T>G

7.88

-10.75

-18.62

D

URM1

P

chrX:49689926T>G

7.72

-10.90

-18.62

D

CLCN5

Y

chr2:118743543A>C

7.08

-11.54

-18.62

D

CCDC93

Y

chr12:31242087T>G

6.89

-11.73

-18.62

D

DDX11

Y

chr2:165600195A>C

6.36

-12.26

-18.62

D

COBLL1

Y

chr6:33256579A>C

5.79

-12.83

-18.62

D

WDR46

P

chr12:131487849T>G

5.32

-13.31

-18.62

D

GPR133

NE

chr11:20142118A>C

4.52

-14.11

-18.62

D

NAV2-AS1

N

chrX:153627303T>G
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-14.82

-18.62

D

RPL10

N

chr3:119222366T>A
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1.35

-2.40

A

TIMMDC1

Y

chr10:116698300T>G
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-15.41

-18.62

D

TRUB1

N

chr13:111932609T>G

0.83

-1.52

-2.35

A

ARHGEF7

Y

rs113825288
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Y

chr8:86131463A>T

7.07

-11.55

-18.62

D

C8orf59

rs67573812

0

NE

chr11:65624562A>C

5.84

-12.78

-18.62

D

CFL1

rs667555

0

N

chr11:20529886G>A

4.71

-13.92

-18.63

D

PRMT3

rs6483700

0.007

NE

chr6:88224673A>C

4.59

-14.04

-18.62

D

RARS2

rs77773960

0

Y

chr16:66547767T>C

2.15

-12.56

-14.71

A

RP11-403P17.5.1

rs2241619

0

Y

8.60

9.73

1.12

A

SPTLC1

EXON

N

chr3:39448804G>T

4.87

7.10

2.23

A

RPSA

INTRON

N

Av. Het.

chr9:94870122C>A

Cryptic Splicing

rsID

Location

C17orf80

Gene

D

Site

-18.63

ΔRi

-10.81

Ri,final

7.82

Ri,initial

chr17:71229465G>A

Validated

Known Variants < 1% Av. Het.

Novel Variants
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chr11:1782979A>C

4.07

5.19

1.11

A

AC068580.6.1

EXON

PS

chr15:75190136G>A

-10.80

3.92

14.71

A

MPI

EXON

N

chr1:153602415A>C

2.22

3.52

1.30

A

S100A1

EXON

N

chr1:44447781T>G

-0.43

3.17

3.59

D

B4GALT2

INTRON

N

Known Variants < 1% Av. Het.
chr1:206647742A>G

6.67

9.68

3.01

D

IKBKE

EXON

rs1539242

0.006

Y

chr10:73039497G>A

-7.59

7.13

14.71

A

UNC5B

INTRON

rs41278006

0.006

N

chr9:131022776G>C

-14.10

4.53

18.63

D

GOLGA2

EXON

rs74686374

0.006

AE

chr3:12447814C>G

0.26

4.13

3.87

A

PPARG

EXON

rs1797895

0.005

N

* Bolded Gene names are previously established tumor driver genes. Legend to symbols in Validation column: Y:
yes validated; YH: yes validated, based on HapMap Phase II Affymetrix Exon array; P: probable: consistent with
mutation altering splicing, but not conclusive; N: not validated; NE: not expressed in cell line. Certain RNAseq results
were not interpretable: LF: low fidelity splicing – significant intron inclusion; PS: multiple pseudogenes or duplicated
exons; AE: rare alternate exon – insufficient data. Under site heading, D: donor, A: acceptor.
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Gene

-2.41

A

FANCD2

Validated

Site

3.54

Av. Het.

ΔRi

5.95

rsID

Ri,final

Leaky

Ri,initial

Table S2 Splicing mutations in cell line U251 predicted by Shannon pipeline

Novel Variants
chr3:10123021T>A

N

Known Variants < 1% Av. Het.
NE

chr3:123554710C>T

8.47

5.29

-3.18

D

MYLK

rs144796555

0

NE

chr7:128117227G>A

5.48

2.47

-3.01

D

METTL2B

rs76349929

0

Y

chr6:121767966T>A

14.37

11.77

-2.60

A

GJA1

rs56199702

0

N

chr16:88051014A>G
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4.34

-2.52

D

BANP

rs6540151

0

NE

chr7:98533187T>G

9.09

7.16

-1.93

A

TRRAP

rs62472016

0

Y

chr15:68445912T>A

16.57

14.72

-1.85

A

PIAS1

rs11633620

0.005
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chr2:32961745T>A

8.99
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-1.85

A

TTC27
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0

P
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6.44

4.72

-1.72

A

MDC1

rs147822906

0

P

chr1:65830299T>G

16.58

15.06

-1.52

A

DNAJC6

rs2296479

0

P

chr6:30679289G>C

3.41

1.96

-1.45

A

MDC1

rs147822906

0

NE

chrX:119402264A>C

11.63

10.30

-1.33

A

FAM70A

rs41300936

0

Y

chr1:33318561T>C

5.86

4.55

-1.32

D

S100PBP

rs702836

0

NE

chr2:37265193A>C

10.76

9.64

-1.12

A

HEATR5B

rs139662639

0

NE

chr17:73698557C>T

9.81

8.70

-1.12

A

SAP30BP

rs820232

0.009

NE

chr7:74152376T>C

7.73

6.64

-1.09

A

GTF2I

rs810377

0

N

Inactivating

10.35

-8.27

-18.62

D

NUBPL

Validated

0

Av. Het.

rs8050128

rsID

WWOX

Gene

A

Site

-3.57

ΔRi

6.67

Ri,final

10.24

Ri,initial

chr16:78312497C>A

Novel Variants
chr14:32142782T>G

NE
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chr19:33904479A>C

10.07

-8.55

-18.62

D

PEPD

N

chr11:34905054G>C

9.32

0.54

-8.78

A

APIP

Y

chr1:43308444A>C

9.07

-9.55

-18.62

D

RP11-342M1.4.1

NE

chr12:4700466T>G

6.83

-11.79

-18.62

D

DYRK4

P

chr3:40570938T>G

5.73

-12.90

-18.62

D

ZNF621

N

Known Variants < 1% Av. Het.
4.77

-6.11

-10.88

A

RP11-512M8.6.1

rs10744155

0

NE

chr6:88224673A>C

4.59

-14.04

-18.62

D

RARS2

rs77773960

0

Y

ΔRi

Site

Gene

Location

-2.43

9.24

11.67

A

KIAA0317

EXON

N

chr21:45539300A>G

4.77

7.77

3.01

D

PWP2

EXON

N

chr19:620369T>G

5.92

7.76

1.84

A

POLRMT

EXON

N

chr2:73228685T>G

4.16

6.00

1.84

A

SFXN5

EXON

N

chr13:73369248A>T

2.91

4.92

2.01

A

PIBF1

INTRON

N

chr17:30303021A>G

1.45

4.63

3.18

D

SUZ12

EXON

N

chr22:50954300T>G

-14.18

4.45

18.63

D

NCAPH2

INTRON

N

chr8:144876251G>C

0.15

3.88

3.73

D

SCRIB

EXON

NE

chr10:135104007G>A

1.62

2.71

1.09

A

TUBGCP2

EXON

NE

chr10:70661701T>G

-16.58

2.06

18.63

D

DDX50

INTRON

N

Av. Het.

Ri,final

chr14:75128861G>C

Cryptic Splicing

rsID

Ri,initial

Validated

chr12:122740009C>T

Novel Variants

Known Variants < 1% Av. Het
chr2:204150427G>C

4.03

5.50

1.47

A

CYP20A1

EXON

rs144732080

0.002

N

chr3:12447814C>G

0.26

4.13

3.87

D

PPARG

EXON

rs1797895

0.005

NE

chr13:20611221G>A

-0.56

2.04

2.61

D

ZMYM2

INTRON

rs75747995

0.009

N
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* Bolded Gene names are previously established tumor driver genes. Legend to symbols in Validation column: Y:
yes validated; P: probable: consistent with mutation altering splicing, but not conclusive; N: not validated; NE: not
expressed in cell line. Certain RNAseq results were not interpretable; AM: ambiguous due to significant exon
skipping/alternative splicing throughout gene. Under site heading, D: donor, A: acceptor.
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Ri,final

ΔRi

Site

Gene

chr18:20529676G>A

6.17

3.16

-3.01

D

RBBP8

Y

chr1:179310449A>G

10.01

7.40

-2.61

D

SOAT1

P

chr1:12318166T>C

11.69

9.97

-1.72

D

VPS13D

Y

chr1:161013165G>T

4.89

3.59

-1.30

D

USF1

Y

chr1:36360707C>A

8.67

7.56

-1.11

A

EIF2C1

N

Leaky

rsID

Ri,initial

Av. Het.

Validated

Table S3 Splicing mutations in cell line A431 predicted by Shannon pipeline

Novel Variants

Known Variants < 1% Av. Het.
18.95

-2.82

A

ZRANB3

rs75842485

0

P

chr1:169272451A>T

9.96

8.49

-1.47

A

NME7

rs10800427

0

P

chr2:32961745T>A

8.99

7.14

-1.85

A

TTC27

rs10200333

0

Y

chr22:36657628T>G

8.94

6.88

-2.06

A

APOL1

rs41368549

0

Y

chr7:29700059G>T

9.43

5.83

-3.59

D

AC007276.5.1

rs74896403

0

PS

chr2:98177124T>G

7.96

4.70

-3.26

D

ANKRD36B

rs11681640

0

PS

chr1:33318561T>C

5.86

4.55

-1.32

D

S100PBP

rs702836

0

AE

chr7:75628461A>T

6.76

4.35

-2.41

A

STYXL1

rs4728538

0

AE

chr15:68445912T>A

16.57

14.72

-1.85

A

PIAS1

rs11633620

0.005

Y

chr17:73698557C>T

9.81

8.70

-1.12

A

SAP30BP

rs820232

0.009

P

Ri,final

ΔRi

Site

Gene

chr1:12064177T>G

9.57

-9.06

-18.62

D

MFN2

Y

chr12:50480538G>C

8.46

-3.21

-11.67

A

SMARCD1

Y

chr11:62341301A>C

7.84

-10.78

-18.62

D

EEF1G

P

Inactivating

rsID

Ri,initial

Validated

21.77

Av. Het.

chr2:136148401A>T

Novel Variants
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chr2:213886187A>C

7.74

-10.88

-18.62

D

AC093865.1.1

PS

chr2:165600195A>C

6.36

-12.26

-18.62

D

COBLL1

N

chr11:20142118A>C

4.52

-14.11

-18.62

D

NAV2-AS1

PS

chr7:98591160G>C

4.33

-7.34

-11.67

A

TRRAP

Y

chr8:103250667A>C

3.60

-15.02

-18.62

D

RRM2B

Y

chr20:55045807G>A

3.41

0.40

-3.01

D

C20orf43

PS

chr22:36722714G>C

2.90

1.18

-1.72

A

MYH9

N

chr12:107374398C>T

2.11

-16.52

-18.63

D

MTERFD3

N

rs10744155

0

PS

chr11:20529886G>A

4.71

-13.92

-18.63

D

PRMT3

rs6483700

0.007

PS

chr14:64669514T>A

1.89

-0.83

-2.72

A

SYNE2

rs189611387

0

Y

5.83

9.57

3.73

D

HNRNPAB

EXON

N

chr16:57180998G>C

-0.56

8.22

8.78

A

CPNE2

EXON

N

chr16:27790837G>C

-1.56

7.22

8.78

A

KIAA0556

EXON

N

chr19:14000568T>G

5.85

7.15

1.30

A

C19orf57

EXON

N

chr8:133822931G>C

5.02

6.47

1.45

A

PHF20L1

EXON

N

chr1:101437592A>C

4.63

6.36

1.73

A

SLC30A7

INTRON

N

chr10:3191408C>A

5.02

6.35

1.33

D

PITRM1

EXON

N

chr14:103871339A>G

-4.68

6.20

10.88

A

MARK3

INTRON

N

chr21:47676584A>G

4.29

5.89

1.60

D

MCM3AP

EXON

N

chr16:27790837G>C

3.15

5.77

2.62

A

KIAA0556

EXON

N

chr22:20113022T>G

-12.96

5.67

18.63

D

RANBP1

EXON

N

Av. Het.

chr5:177637135C>G

Cryptic Splicing

rsID

Location

RP11-512M8.6.1

Gene

A

Site

-10.88

ΔRi

-6.11

Ri,final

4.77

Ri,initial

chr12:122740009C>T

Validated

Known Variants < 1% Av. Het.

Novel Variants
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chr6:7227103T>G

-14.30

4.34

18.63

D

RREB1

INTRON

N

chr16:90051055G>A

1.05

3.58

2.52

D

AFG3L1P

EXON

PS

Known Variants < 1% Av. Het.
chr1:206647742A>G

6.67

9.68

3.01

D

IKBKE

EXON

rs1539242

0.006

N

chr3:12447814C>G

0.26

4.13

3.87

D

PPARG

EXON

rs1797895

0.005

LF

chr2:232087474A>G

-15.64

3.00

18.63

D

ARMC9

EXON

rs1626450

0.0004

N

* Bolded Gene names are previously established tumor driver genes. Legend to symbols in Validation column: Y:
yes validated; P: probable: consistent with mutation altering splicing, but not conclusive; N: not validated; LF: low
fidelity splicing – significant intron inclusion; PS: multiple pseudogenes or duplicated exons; AE: rare alternate exon –
insufficient data. Under site heading, D: donor, A: acceptor.
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